Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation.
J Hepatol
; 43(3): 458-64, 2005 Sep.
Article
en En
| MEDLINE
| ID: mdl-16005538
ABSTRACT
BACKGROUND/AIMS:
To evaluate the therapeutic efficacy of percutaneous ethanol injection (PEI) for patients with < or = 3 lesions of small (< or = 3 cm diameter) hepatocellular carcinoma (HCC).METHODS:
PEI was applied to 270 patients with small HCC as the first-line treatment option during a 20-year period.RESULTS:
(1) There was no treatment-related deaths, and only 2.2% of severe complications; (2) PEI induced a complete response of all HCCs according to CT evaluation performed within one month after the procedure, and the local recurrence rate at 3 years was 10%; (3) the overall 3- and 5-year survival rates after treatment were 81.6 and 60.3%, respectively, but the rates were higher, 87.3 and 78.3%, in Child A patients with a solitary tumor < or = 2 cm in diameter; (4) factors significantly influencing survival were liver function (P = 0.0033) and serum alpha-fetoprotein level (P = 0.0014), and (5) the recurrence rate at remote sites in the liver was lower in patients with HCC < or = 2 cm (P = 0.0395) and in those with a solitary HCC (P < 0.0001) according to Cox's proportional hazard model. (6) Radiofrequency ablation would not have been performed in approximately 25% of these patients.CONCLUSIONS:
PEI is considered a reliable treatment for small HCC in terms of safety and efficacy.
Buscar en Google
Colección:
01-internacional
Asunto principal:
Carcinoma Hepatocelular
/
Etanol
/
Neoplasias Hepáticas
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Hepatol
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Japón